Myriad Genetics, Inc. (FRA:MYD)

Market Cap	386.20M -40.3%
Revenue (ttm)	702.23M -1.6%
Net Income	-311.64M
EPS	-3.37
Shares Out	n/a
PE Ratio	n/a
Forward PE	166.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	115
Open	4.035
Previous Close	4.272
Day's Range	4.035 - 4.035
52-Week Range	3.300 - 7.100
Beta	n/a
RSI	55.81
Earnings Date	May 5, 2026

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1991
• Employees: 2,700
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MYD

Financial Performance

In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.

Financial numbers in USD